Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Peginterferon Alfa
Peginterferon Alfa
BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients
Yahoo/BusinessWire
Sun, 09/18/11 - 12:14 pm
Bristol-Myers Squibb
BMS-790052
Peginterferon Alfa
Ribavirin
hepatitis C
